Topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107 - Suven Life Sciences Ltd

Code BSE: 530239 NSE: $SUVEN Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development Favorable safety profile with no dose-limiting toxicities. a) Achieved projected therapeutic exposures in plasma and at the target site. b) Robust pharmacodynamic activity demonstrating evidence of CNS activity. c) PK assessments showed no clinically meaningful differences between male and female. d) Food intake had no clinically relevant impact on the PK of SUVN-I6107. e) Pharmacodynamic Biomarker assessments demonstrated evidence of increased alertness and enhanced information processing.